Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-11

Study Completion Date

2021-10-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers are observing the values of proEnkephalin (PENK) via a blood draw in hospitalized patients that are volume overloaded requiring diuresis. If changes in PENK are found, physicians may predict values of change in kidney function during treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Proenkephalin for Prediction of Contrast-Associated Kidney Events

NCT03989505

Contrast-induced Nephropathy Acute Kidney Injury Coronary Artery Disease

COMPLETED

Protocol to Assess the Severity of Acute Kidney Injury

NCT00673244

Acute Kidney Failure

COMPLETED NA

AKI Cardiosurgery Diagnostic Study (AKI-CDS)

NCT03632538

Acute Kidney Injury Renal Replacement Therapy

UNKNOWN

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

NCT06652100

Acute Kidney Injury

ACTIVE_NOT_RECRUITING

Proenkephalin A and Kidney Replacement Therapy

NCT04879706

Acute Kidney Injury

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study will be to probe if values of proEnkephalin, called PENK in this proposal, can identify those patients who develop AKI. This biomarker is an opioid that is rapidly released in response to renal injury. At a cut-off value of 100pmol/L, it has been reported to have excellent sensitivity and specificity for detecting renal injury. PENK has been shown to be prognostic of WRF and outcomes in patients with acute heart failure but requires evaluation of efficacy in detecting AKI in standard of care clinical practice settings. In this study we propose to evaluate the baseline presence of plasma and/or serum levels of biomarkers of renal injury and changes in these biomarkers during the course of in-hospital intravenous diuretic therapy. The question is if threshold values of the biomarkers can be identified and if those threshold values would indicate a clinically significant change in renal function that would warrant a change in diuretic therapy to occur. In this context the quantitative assessment of intravascular volume will provide objective corroboration as to volume status in relation to biomarker levels and changes during treatment. If this approach can be proven to be fruitful, it would be anticipated that a subsequent study, a clinical trial, to test the hypothesis that biomarkers of AKI, specifically PENK, could be used to identify and avoid AKI in hospitalized patients with decompensated HF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Volume Overload Decompensated Heart Failure Systolic Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with know chronic systolic heart failure

Subjects with know chronic systolic heart failure (LVEF\<50%) admitted to SMH Heart Failure Medical Service for decompensated HF with clinical findings of volume overload requiring advanced diuretic therapy intervention and management will receive daily blood draws and quantitative blood volume analysis

Group Type EXPERIMENTAL

Blood Collection

Intervention Type PROCEDURE

Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.

Blood Volume Analysis

Intervention Type PROCEDURE

A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Collection

Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.

Intervention Type PROCEDURE

Blood Volume Analysis

A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* LVEF \<50% measured within 6 months of index hospitalization
* Clinically identified volume overload with at least one sign of volume overload (pre-admission fluid weight gain, edema, increased DOE, PND, orthopnea, JVD on examination) and a need for intravenous diuretic therapy

Exclusion Criteria

* Baseline sCr \>3.0mg/dL and K+ \<3.0 and \>5.5mEq/L
* Hemoglobin \< 9.0g/dL
* Systemic systolic blood pressure consistently \<100mm Hg
* Patients being treated with hemodialysis, CKD stage 5 or s/p renal transplantation
* S/P cardiac transplant or LVAD implantation/total artificial heart
* Pregnancy or of child bearing potential
* Allergy to iodine
* Unable to provide informed consent to participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No